Renaissance Capital logo

Freeline Therapeutics Priced, Nasdaq: FRLN

Phase 1/2 biotech developing gene therapies for hemophilia and rare diseases.

Industry: Health Care

First Day Return: 0.0%

We are a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. We aim to deliver one-time gene therapy treatments that provide functional cures through permanently sustained physiological protein levels, leveraging the high expression enabled by our proprietary gene therapy platform. Our initial focus is on developing treatments for monogenic diseases with high unmet need. We are a fully-integrated biotechnology company with internal expertise and capability across the value chain in gene therapy, including expression platform, research, manufacturing, clinical development and commercialization. Our pipeline includes two programs in the clinic and two late-stage preclinical product candidates, as well as research programs targeting novel applications for systemic gene therapy, for which we have, through owned and in-licensed intellectual property rights, development and worldwide commercial rights.

Freeline Therapeutics (FRLN) Performance

Created with Highcharts 10.3.2Chart context menuFRLN vs. IPO Index (IPOUSA)Oct '20Jan '21Apr '21Jul '21Oct '21Jan '22Apr '22Jul '22Oct '22Jan '23Apr '23Jul '23Oct '23Jan '24Apr '24Jul '24Oct '24Jan '25-50%0%+ 50%-100%+ 100%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index